Skip to main content

Viridian Therapeutics, Inc. (VRDN) Stock Analysis

Recovery setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $15.97: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 4.22; Below-average business quality.

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under Priority Review with PDUFA June 30, 2026) and elegrobart (SC IGF-1R, Phase 3 REVEAL-1/2 results expected Q1/Q2 2026) for thyroid eye disease, plus FcRn inhibitors... Read more

$15.97+91.2% A.UpsideScore 5.5/10#45 of 157 Biotechnology
QualityF-score3 / 9FCF yield-10.27%
Stop $14.85Target $30.54(analyst − 10%)A.R:R 6.1:1
Analyst target$33.94+112.5%16 analysts
$30.54our TP
$15.97price
$33.94mean
$50

Sell if holding. Engine safety override at $15.97: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 4.22; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 63. Score 5.5/10, moderate confidence.

Passes 6/9 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.

Val5.4Qual1.6Grw10.0Mom3.9Sent8.8Ins7.0Peer3.1Tech3.4Risk3.15.5OVERALL

Recent Developments — Viridian Therapeutics, Inc.

Latest news

Generated 2026-05-20T20:21:22Z.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.4
Mkt Cap$1.8B
EV/EBITDA-2.8
Profit Mgn0.0%
ROE-58.1%
Rev Growth95.8%
Beta0.82
DividendNone
Rating analysts24

Quality Signals

Piotroski F3/9

Options Flow

P/C4.22bearish
IV67%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·2 ceiling hits

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Moat
4.2
Current Ratio
5.0
Cash-burning: FCF -257% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.5
Value Rank
2.2
Growth Rank
8.1
Industry growth leader

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Bollinger
4.4
Support Resistance
5.9

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.1
Obv
1.0
Rsi
3.7
Ma Position
4.5
Macd
10.0
Volume distribution (falling OBV)Below 200-MA, MA slope flat
GatesMomentum 3.9<4.5INSIDER 1.12%=EXTREMEDeath cross (50MA < 200MA)A.R:R 6.1 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
63 · Neutral
↑ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $13.18Resistance $20.00

Price Targets

$15
$31
A.Upside+91.2%
A.R:R6.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.6 < 4.0)
! Momentum score 3.9/10 — below 4.5 minimum
! Insider activity: 1.12%=extreme

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is VRDN stock a buy right now?

Sell if holding. Engine safety override at $15.97: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 4.22; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $14.85. Score 5.5/10, moderate confidence.

What is the VRDN stock price target?

Take-profit target: $30.54 (+91.2% upside). Prior stop was $14.85. Stop-loss: $14.85.

What are the risks of investing in VRDN?

Quality below floor (1.6 < 4.0).

Is VRDN overvalued or undervalued?

Viridian Therapeutics, Inc. trades at a P/E of N/A (forward -6.4). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about VRDN?

24 analysts cover VRDN with a consensus score of 4.2/5. Average price target: $34.

What does Viridian Therapeutics, Inc. do?Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under...

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under Priority Review with PDUFA June 30, 2026) and elegrobart (SC IGF-1R, Phase 3 REVEAL-1/2 results expected Q1/Q2 2026) for thyroid eye disease, plus FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune disorders. No products approved; $874.7M cash as of December 31, 2025.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.) · HRMY (Harmony Biosciences Holdings, I) · GLPG (Galapagos NV)